DA-1726

Sept. 9, 2026: MetaVia Inc. (NASDAQ: MTVA) reported preclinical tissue distribution data for DA-1726, its once-weekly subcutaneous GLP1R/GCGR dual agonist being developed for obesity and MASH. After subcutaneous dosing, DA-1726-derived radioactivity was slowly absorbed and broadly distributed, with the highest tissue exposure in adipose tissue and liver; tissue-to-plasma ratios increased over time, indicating prolonged tissue retention through the final 144-hour assessment. Minimal radioactivity was detected in the central nervous system.

The company said these findings support DA-1726’s once-weekly pharmacokinetic profile and provide mechanistic rationale for prior clinical observations. It referenced previously reported Phase 1 obesity data in which patients receiving 48 mg had a mean 9.8 cm reduction in waist circumference after eight weeks (Day 54).

MetaVia also highlighted its ongoing 24-week dose-titration study of DA-1726, with 16-week topline data expected in Q4 2026 and 24-week topline results expected in Q1 2027.